Abstract 116P
Background
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. The prognostic role of Fibrous sheath interacting protein 1 (FSIP1) in LUAD remains unclear. Thus, this study aims to identify and validate the prognostic value of FSIP1 in LUAD and explore its molecular functions.
Methods
Single-cell RNA sequencing (scRNA-seq) data of LUAD patients were collected from Gene Expression Omnibus (GEO) database, the major cell types were identified based on known markers. Additionally, the expression of FSIP1 was detected in 180 LUAD samples, Kaplan-Meier (KM) analysis of high- and low-expression patients was conducted. Univariate and multivariate Cox regression analyses were utilized to assess the prognostic ability of FSIP1. Then, FSIP1-silenced human LUAD cell lines were constructed, and the functions of FSIP1 were explored. Finally, immune infiltration analysis was performed in LUAD patients.
Results
In this study, we identified LUAD FSIP1+ cancer cells by using scRNA-seq data from GEO database. Additionally, we investigated the protein level and prognostic value of FSIP1 in 98 LUAD patients using Tissue Microarray. Compared with the adjacent, FSIP1 was higher expressed in LUAD tissues. KM analysis revealed that the 5-year OS rate to be 30% to 59% (FSIP1High vs FSIP1Low) in Tissue Microarray. Univariate and multivariate COX regression showed that FSIP1 should be an independent factor in poor prognosis. The receiver operating characteristic curve (ROC) and time-ROC curve both indicated that FSIP1 had a good performance in prognostic model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that FSIP1 was associated with migration. Migration assay and Western blotting showed that FSIP1 influenced cell migration and PI3K/AKT pathway. FSIP1 could influence the immune cell infiltration in lung adenocarcinoma patients.
Conclusions
This study verified that FSIP1 could serve as a valuable prognostic biomarker in LUAD and analyzed its impact on the disease and its association with the immune infiltration. The findings of this research provide valuable insights into the understanding of LUAD and could potentially lead to the development of new treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - 23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcgRIIIa activation
Presenter: Kim Gerrick
Session: Poster session 08
154P - Phase II study of nivolumab and relatlimab utilizing single cell analysis of circulating T cells reveals immune features associated with response to dual PD-1 and LAG-3 inhibition
Presenter: James Dollar
Session: Poster session 08
155P - The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)
Presenter: Robert Watson
Session: Poster session 08
156P - Microbiota-related multiomics to assess the clinical relevance of antibiotics (ATB) in immunotherapy (ICI)
Presenter: Adele Bonato
Session: Poster session 08
157P - Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Presenter: Joao Gorgulho
Session: Poster session 08
158P - Patterns of immune-related adverse events in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08
160P - Predicting immune-related adverse events using biomarkers in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08
161P - Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment
Presenter: Ignacio Melero
Session: Poster session 08
162P - Exploiting gp100-specific antibodies isolated from immune checkpoint inhibitor-responsive melanoma patients to target tumor cells
Presenter: Lukas Flatz
Session: Poster session 08